Best of IBD Forum 2020

1.50 CME
$0 FEE
Best of IBD Forum 2020


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by educational grants from AbbVie Inc. and Pfizer, Inc.  

Activity Description

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, affects an estimated 3 million adults in the United States and is increasing in incidence and prevalence. In the quest to optimize outcomes, clinicians providing care to patients with IBD face numerous challenges, including determining disease severity, treating the newly diagnosed patient, understanding and incorporating the use of available biologic agents and newer treatment options with novel mechanisms of action, and applying strategies for therapeutic drug monitoring. Therefore, continuing education is vital to help clinicians stay abreast of the latest evidence-based management approaches. The faculty of IBD Forum 2020 will review the current IBD guidelines, biologic agents, and combination therapies and will address other identified educational gaps.

Target Audience

The intended audience for the activity is gastroenterologists and other health care professionals involved in the management of patients with IBD.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Review current guidelines on treat-to-target approaches in the management of IBD.
  • Assess and monitor disease severity in patients with IBD, using evidence-based modalities that improve the care of established and new patients.
  • Incorporate the use of biologics, combination therapies, and emerging agents with novel mechanisms of action in patients with IBD refractory to current therapeutic options.
  • Incorporate the use of biomarkers and other therapeutic regimens that may improve patient outcomes and mucosal healing in IBD.
  • Apply therapeutic drug monitoring as needed to optimize the management of IBD.

Activity Chair

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine of the
University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania
Philadelphia, PA


Peter D.R. Higgins, MD, PhD, MSc
Professor of Internal Medicine
University of Michigan
Ann Arbor, MI

Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, April 28, 2020, through April 27, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the activity, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Activity Chair and Faculty report the following relationship(s)

Peter D.R. Higgins, MD, PhD, MSc
Consulting Fee: AbbVie, Arena, Genentech, Lycera, Pfizer, Takeda
Contracted Research: NIH, Crohn’s & Colitis Foundation

Stephen B. Hanauer, MD
Consulting Fee: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Nestle, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Takeda, TiGenex, UCB Pharma, VHsquared
Speakers Bureau: AbbVie, Janssen, Takeda
Contracted Research (paid to institution): AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB Pharma
Data and Safety Monitoring Board: Arena Pharmaceuticals, Bristol-Myers Squibb

Gary R. Lichtenstein, MD
Royalty: SLACK Incorporated
Consulting Fee: AbbVie, Celgene, Cellcuetix, Endo Pharmaceuticals, Ferring, Gilead, Janssen, Lilly, Luitpold/American Regent, Merck, Morphic Therapeutic, Pfizer, Prometheus, Romark, Salix/Valeant, Shire, Takeda, UCB
Contracted Research: Celgene, Janssen, Salix/Valeant, Shire, UCB
Consulting Fee (paid to institution): Janssen, Pfizer, Takeda
Data and Safety Monitoring Board: Lilly
Author Honoraria: McMahon Publishing, UpToDate
Editor Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media

Millie D. Long, MD, MPH
Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at